Anti-Hypertensive Drugs - United Kingdom

United Kingdom

The projected revenue for the Anti-Hypertensive Drugs market in the United Kingdom is expected to reach €0.58bn in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 1.01%, leading to a market volume of €0.61bn by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to €11,400.00m in 2024.
The United Kingdom is witnessing a surge in the demand for innovative anti-hypertensive drugs, driven by an aging population and increasing awareness about the importance of managing hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Anti-Hypertensive Drugs market in United Kingdom has been steadily growing over the past few years.

Customer preferences: With an aging population and rising obesity rates, hypertension has become a major health concern in the UK. As a result, there is a growing demand for anti-hypertensive drugs among patients. Additionally, there is an increasing preference for combination therapies that offer greater efficacy and convenience.

Trends in the market: The market for anti-hypertensive drugs in the UK is dominated by branded drugs, with a few key players holding significant market share. However, there has been a recent trend towards the use of generic drugs, as they offer cost savings for both patients and healthcare providers. This trend is expected to continue, particularly as more drugs come off-patent in the coming years.

Local special circumstances: The UK has a National Health Service (NHS) that provides free healthcare to all residents. As a result, the pricing and reimbursement of drugs is heavily regulated by the government. This can make it challenging for pharmaceutical companies to introduce new drugs to the market, as they need to demonstrate both clinical efficacy and cost-effectiveness.

Underlying macroeconomic factors: The UK economy has been relatively stable in recent years, with moderate GDP growth and low unemployment rates. However, there is ongoing uncertainty surrounding Brexit and its potential impact on the economy. This could have implications for the pharmaceutical industry, particularly if there are changes to regulations around drug pricing and reimbursement.Overall, the Anti-Hypertensive Drugs market in the United Kingdom is expected to continue growing in the coming years, driven by an aging population and rising rates of hypertension. However, pharmaceutical companies will need to navigate a complex regulatory environment and increasing competition from generic drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.